Alliance Study to Explore Vaccine Therapy in Recurrent GBM to Extend Overall Survival

Primary malignant brain tumors are uniformly fatal, and the five-year survival rate for the highest grade of malignant glial neoplasm (GBM) is now less than 4 percent. Improvements in treatment methods have provided some progress; however, how long patients survive (called median survival) remains at just more than one year from initial diagnosis. Current therapies have shown modest improvement in survival of recurrent GBM patients.

In a new clinical trial (A071101), Alliance researchers


2015 Spring Group Meeting | May 13-17
2015 Fall Group Meeting | November 4-8
2016 Fall Group Meeting | November 2-5
2017 Fall Group Meeting | November 1-4

Loews Hotel Chicago O'Hare, Rosemont, IL 60018
open to all Alliance members



RSS Feed Widget